Figure 2From: Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer Incremental cost-effectiveness scatterplot and acceptability curve of RS-assay-guided therapy versus CCP-guided therapy for pre- and post-menopausal women. Sampling distributions and summary estimates of cost, efficacy, and variance were based on 1000 replicates.Back to article page